Polarean Imaging PLC is a leading medical technology company with a strong emphasis on innovation and excellence. The company is committed to improving the diagnosis and treatment of respiratory diseases through its advanced portfolio of hyperpolarized magnetic resonance imaging (MRI) solutions. Polarean Imaging PLC aims to provide accurate and precise imaging techniques that enable healthcare professionals to make informed decisions and provide the best possible care to patients. With a focus on research and development, Polarean Imaging PLC strives to constantly push the boundaries of medical imaging technology, ensuring a brighter and healthier future for individuals worldwide.

Polarean Imaging PLC is primarily present in the United Kingdom and the United States.

Polarean Imaging PLC has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of its proprietary hyperpolarized gas technology. This groundbreaking technology enables the production of hyperpolarized xenon and helium gases, used in innovative MRI imaging techniques. Additionally, Polarean Imaging PLC has received regulatory approvals for its products, including the Drug Master File from the U.S. FDA. The company has also formed strategic partnerships with leading medical institutions and organizations globally, further enhancing its market presence. These achievements demonstrate Polarean Imaging PLC's commitment to advancing medical imaging solutions and cementing its position as a key player in the industry.

Polarean Imaging PLC, founded in 2009, is a leading medical technology company focused on the development and commercialization of novel drug-device combination products. The company specializes in the production of hyperpolarized xenon gas (129Xe), a unique imaging agent used in magnetic resonance imaging (MRI) to enhance image quality and provide insights into various pulmonary disorders. Polarean Imaging PLC's proprietary technologies and expertise in hyperpolarized gas allow for improved diagnosis and monitoring of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. With a strong commitment to advancing respiratory healthcare, Polarean Imaging PLC is revolutionizing patient care through innovative imaging solutions.

The main competitors of Polarean Imaging PLC in the market include companies such as General Electric Company (GE), Siemens Healthineers AG, and Fonar Corporation.

Polarean Imaging PLC is primarily active in the healthcare and medical imaging industries.

The business model of Polarean Imaging PLC revolves around the development and commercialization of advanced medical imaging technology. As a leading company in the field of hyperpolarized gas MRI, Polarean Imaging PLC focuses on enhancing the quality and accuracy of pulmonary imaging. By leveraging its proprietary technology, the company aims to provide healthcare professionals with tools to improve the diagnosis and management of respiratory conditions such as chronic obstructive pulmonary disease (COPD) and lung cancer. Polarean Imaging PLC's innovative approach enables non-invasive and precise assessment of lung function, offering valuable insights for personalized treatment decisions and clinical research.

Razmerje cena/dobiček Polarean Imaging je −0,10.

Koeficient Polarean Imaging cene in prihodkov je 2,92.

AlleAktien kakovostni rezultat za Polarean Imaging je 3/10.

pričakovana Polarean Imaging promet je 2,02 mio. USD.

Dobiček pričakovana Polarean Imaging je −60,96 mio. USD.

Polarean Imaging PLC is an emerging company in the medical technology industry that specializes in the manufacturing of medical imaging solutions. The company is headquartered in the UK and is listed on the AIM market of the London Stock Exchange. Polarean Imaging's business model is based on the production and sale of hyperpolarization systems, which allow radiologists to obtain more accurate images of the internal organs of the human body. With this technology, doctors can now create real-time images that help detect diseases early and improve treatment options. Polarean's main product is a hyperpolarization system called Polarcath, which measures the oxygen supply to the heart. This system is the first approved method for measuring oxygen supply in patients with cardiovascular diseases. However, Polarean also plans to develop additional hyperpolarization systems to measure other parameters and other diagnostic systems. Polarean has three main business areas: clinical care, research and development, and sales and marketing. In the clinical care field, Polarean collaborates with leading hospitals and medical centers in the UK and Europe to introduce its hyperpolarization systems into practice. The systems are used in clinics to perform pre-treatment examinations and evaluate the effectiveness of treatments. In addition, the company works closely with medical societies to further develop the technology and standardize existing procedures. Polarean's research and development department is actively working on the development of new technologies to improve medical imaging. The company invests several million annually in research to improve the performance of its systems and develop new applications. The focus is on advancing hyperpolarization technology to produce cost- and time-efficient systems. Polarean's sales and marketing department is responsible for the sales and marketing of the hyperpolarization systems. Customer contact is a primary focus. The company has a wide network of distribution partners and sales personnel worldwide, who drive the dissemination of the technology. In conclusion, Polarean Imaging PLC is an innovative company that aims to improve the diagnosis and treatment of diseases through the introduction of new technologies in medical imaging. The company takes a holistic approach that spans from research and development to marketing and clinical care. With extensive investments in research and development, a strong market position, and close collaboration with leading hospitals, Polarean Imaging will establish itself as one of the key players in the medical technology industry.

Polarean Imaging izplača dividendo v višini 0 USD, razdeljeno na izplačil letno.

Dividende za Polarean Imaging trenutno ni mogoče izračunati ali pa podjetje ne izplačuje dividend.

ISIN od Polarean Imaging je GB00BF3DT583.

WKN od Polarean Imaging je A2JHGR.

Oznaka delnice Polarean Imaging je POLX.L.

V zadnjih 12 mesecih je Polarean Imaging izplačal dividendo v višini . To ustreza približni donosnosti dividend . V prihajajočih 12 mesecih bo Polarean Imaging predvidoma izplačal dividendo v višini 0 USD.

Trenutni donos od dividend za Polarean Imaging znaša .

Polarean Imaging izplačuje četrtletno dividendo. Ta se izplačuje v mesecih .

Polarean Imaging je v zadnjih 0 letih vsako leto izplačeval dividend.

V naslednjih 12 mesecih se pričakuje dividende v višini 0 USD. To ustreza dividendnemu donosu 0 %.

Polarean Imaging je razvrščen v sektor 'Zdravje'.

Da si prejel zadnjo dividendo Polarean Imaging z dne 29. 7. 2024 v višini 0 USD, si moral imeti delnico v depoju pred dnevom brez pravice do dividende (Ex-Tag) 29. 7. 2024.

Zadnje izplačilo dividende je bilo 29. 7. 2024.

V letu 2023 je Polarean Imaging 0 USD izplačal kot dividende.

Dividende od Polarean Imaging se izplačujejo v USD.